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Abstract
Adoptive T cell therapy (ACT) is getting acknowledged as the Advanced 
Therapy Medicinal Products (ATMPs) in many countries and it has evolved as one 
of the newest regimens to treat cancer. Developed gradually by the basic under-
standing of cells, involved in innate and adaptive immunity, ACT has emerged as 
one of the successful immunotherapies in recent times. It broadly includes various 
cell types such as stem cells, T cells, dendritic cells and Natural Killer cells. By the 
applications of genetic engineering and advanced cell culture techniques, these 
cells from patients’ blood, can be manipulated to train them for better efficacy 
against specific tumor cells. However, only some cells’ subsets have shown promis-
ing regression for certain cancer cells types. To understand the reason behind this, 
technical knowledge about the tumor antigens presentation, tumor microenviron-
ment (TME), hosts’ immune responses and possible issues in the manufacturing of 
adoptive cellular material for infusion in patients are being explored further. This 
chapter brings together development of immune cells from basic research to clinical 
use, newer approaches which have been taken to address the resistance of ACT and 
future promises of this therapy.
Keywords: immunotherapy, advanced therapy medicinal products,  
adoptive T cell therapy, tumor microenvironment, TCR T cell Therapy,  
CAR T cell therapy
1. Introduction
Human body has a natural tendency to fight against diseases including cancer, 
aided by its immune system. So far, the journey of understanding mechanisms of 
tumor suppression by immune system and immune suppression by tumor cells, has 
been overwhelming. The ability of immune cells to differentiate between self and 
non-self is the key for immune response against cancer cells [1]. However, as cancer 
cell is actually a transformed self-cell, its ability to escape immune recognition is 
quite probable and a reason of cancer progression.
The treatment of cancer in the new era has shifted its focus from conventional 
treatment to physiological treatment, which involves the modification of immune 
system. This has also led to a concept of personalized treatment where an individual 
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immune system of patient is manipulated rather immune responses obtained 
based on general population. The efficacy of the immune cells is modified so that 
its tumor suppression function is improved. This strategy has shown better out-
comes and therefore has drawn attention of researchers and clinicians and is now 
a preferred choice for cancer treatment. The efforts to design universal immune 
cell-based immunotherapy are also being explored besides personalized immuno-
therapy [2]. Numbers of approaches have been developed to treat cancer cells using 
immune-based technology broadly known as cancer immunotherapy (Figure 1 and 
Table 1).
Among all these immunotherapies, cell-based cancer immunotherapy is get-
ting popular day by day [18–20]. The ability of immune system to inhibit tumor 
growth and cure it, has been exploited in the development of anti-neoplastic 
immunotherapy. The immune cells play a key role in adoptive cell therapy (ACT). 
This is achieved by either expanding the autologous cancer-cognate lymphocytes 
or empowering them by genetic modifications. These alterations are done ex-
vivo and then these cells are infused back to patient to fight against the cancer 
(Figure 2).
Cancer treatments by general immunotherapy have their own limitations due 
to personal variation in the immune response. In such cases, precision medicine 
through adoptively modified cellular transfers is being preferred lately. The cells 
to be transferred may be autologous (self-derived) or allogeneic (donor derived) 
depending upon the availability. These cells undergo various genetic modifications 
to suit the cancer types. Allogeneic cells are chosen on the basis of haplo-identical 
donors, or immune-suppressive conditioning to the patient.
This chapter outlines the emergence and evolvement of ACT, advance-
ments particularly with genetic engineering of autologous cells, treatment 
approaches, evidences for its effectiveness in refractory patients, and future 
directions of ACT.
Figure 1. 
Different approaches to cancer immunotherapy. Arrow indicates different modes through which 
immunotherapy can be performed. Application of T cells is the foremost choice of the cellular advancement 
for ACT.
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Types Salient features Ref.
Antibody • Therapeutic use of monoclonal antibodies (mAbs)
• Tumor killing by cytotoxicity; Fc mediated immune effector engagements,  
non-restricted activation of T-cells and blockade of inhibitory signaling.
[3–5]
Cytokines • Molecular messengers with anti-tumor property, majorly secreted by immune 
cells
• Pro-inflammatory cytokines limit tumor cell growth by stimulating the 
cytotoxic activity of immune cells against tumor cells.




• Genetically engineered viruses carrying tumor suppressor genes
• Work like the gene therapy
• When administered, self-replicate in the tumor and induce apoptosis.
• Modulate tumor microenvironment and provide anti-cancer immunity
[7]
Vaccine • Meant to treat cancer as a personalized cancer vaccine
• Helps the patient’s immune system for cancer killing and relapses.
• May consist of dendritic cells, tumor cell lysate, nucleic acids (DNA and 
mRNA), or neoantigens.
• Approaches: dendritic cells engineered to express high levels of tumor-associ-
ated target antigens, and delivered to relevant lymph nodes to activate T-cells
• The DNA and mRNA-based vaccines: taken up by APCs and present to T-cells to 
induce their activation
• Tumor neoantigen: tumor specific antigens for the development of cancer 




• Chemotherapeutics as regulator of immune cells
• Indoleamine 2,3-dioxygenase-1 inhibitors boost cellular immunity
[16, 17]
The salient features with examples of various approaches toward the cancer immunotherapy have been discussed. 




Approach toward adoptive cellular therapy. Cells of interest to perform ACT may be collected through 
surgery or apheresis. Next, either these cells can be re-infused to patient after its proper expansion or genetic 
manipulations depending upon cancer types.
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2. Emergence of ACT
The concept of ACT was first developed more than fifty-five years back when 
immune lymphocytes were successfully used to inhibit growth of sarcoma in an 
animal model [21].
Further, efforts were made to augment the potential of ACT by inducing activa-
tion and proliferation of immune cells in use, which was achieved by the use of 
recombinant IL2. The IL-2 has been known to potentiate immunological functions 
and later, its use as T cell growth factor were also recommended [22].
In cell based or cellular therapy, autologous or allogenic stem cells, progenitor 
or primary cells were the choice of possible cell types, which were modified ex-vivo 
and transfused into the patient for disease regression [2, 18, 19]. Cellular therapy’s 
outcomes were better studied in the case of cancer as it was easy to readout its 
regression and thus, cancer was chosen first for treatment by cellular therapy. 
However, lately, this strategy has also been tested for treating cardiovascular, neu-
rological and bone diseases [23]. The choice of cells to develop immunotherapy was 
from innate and adaptive immune systems as these cells play a key role in control-
ling cancer progression [24].
Further, initial failures of cell- based therapy were reported due to the role of T 
cells as the mediators of allograft rejection and also due to the host immune inhibi-
tory factors [2, 25]. Therefore, measures were taken prior to ACT such as use of 
syngeneic lymphocytes for transfer to minimize the failures of the same [25]. Thus, 
ACT was developed as a biomedical procedure where the immune cells of the cancer 
patient, which have high anticancer activity, are expanded, modified and returned 
to the patients [2, 18, 19].
During eighties, the antitumor activities were reported in cells like natural 
killer (NK) and lymphokine-activated killer cells [26–30]. These cells directly 
recognize antigens present on tumor cells and kill them, whereas T cells recognize 
tumor antigens when presented with major histocompatibility complex (MHC) 
[31]. However, each cell has different anti-tumor potential. With advancements in 
immuno-technologies, such as fluorescence activated cell sorter, molecular markers 
were assigned on various immune cells to define them properly [32, 33]. This led to 
the classification of lineages and subtypes of immune cells. Thus, selection of cells 
was made and this followed their manipulation ex-vivo for ACT.
So far various cell types such as stem cells, T cells, dendritic cells and NK cells 
from patients are successfully used and have shown promising results in cancer 
regression (Figure 1). Dendritic cells (DCs) regulate innate immune response 
and due to its nature of antigen presentation, it may induce adaptive response. 
Tumor antigen exposed DCs may play a critical role in enhancing cytotoxic 
activities of immune cells. Therefore, DCs are used as an anti-tumor therapeutic 
vaccines or to enhance the stimulation of cytotoxic T cells by appropriate antigen 
 presentation [34].
Different subset of T cells (gamma/delta T cells, regulatory T cells, helper and 
cytotoxic T lymphocytes) respond differently for various tumor subtypes [35]. 
Interestingly, some T cell subtypes confer advantage over other in reducing tumor 
volume [36].
3. Evolving modes and mechanisms of ACT
ACT developed in different ways has different mechanisms to target cancer cells. 
These are the foremost cellular technology adopted for cancer treatment after their 
validations and regulations through various clinical trials.
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3.1 Tumor infiltrating lymphocytes (TILs)
Under the immune surveillance, lymphocytes differentiate between self and 
non-self-cells and antigens. Any self-cell when gets transformed and starts prolifer-
ating as cancer, lymphocytes infiltrate into that site, recognize abnormally growing 
cells and activate themselves to remove these not so self, cancerous cells. These 
lymphocytes are named as Tumor Infiltrating Lymphocytes (TILs). It so happens 
sometimes that these TILs fail to perform their function efficiently which may lead 
to cancer progression. In such cases, it was found that the TILs are not enough in 
number to show effective cytotoxicity, though have ability to specifically recognize 
tumor cells, stop their growth and eventually kill them. Thus, to develop any cel-
lular therapy, the first and the foremost approach was to expand TILs, which have 
infiltrated into the tumor site with anti-tumor potential. These cells can be isolated 
from cancer origin tissue by resection and expanded ex-vivo to a sufficient number 
to improve their anti-tumor activity. These are then infused back into the patient as 
ACT therapy (Figure 3a). The TILs used in the therapy are autologous lymphocytes 
as these are derived from the tumor site.
Hence, for the development of ACT, antitumor lymphocytes are grown in-vitro 
up to a number of 1011–1012, followed by a process of selection of specific tumor 
recognizing cells with effector functions. These cells when infused in the patient, 
behave like live drug, which proliferate when encounter tumor antigen in the host 
and help in tumor regression. Though the process of cellular expansion in-vitro does 
not absolutely match with in-vivo environment around the tumor, which has certain 
immune inhibitory responses. Thus, in ACT, a favorable tumor microenvironment 
is necessary prior to the therapy which should support the anti-tumor immune 
function of the infused TILs [37].
3.2 Genetic manipulations of T cells
Sometimes in certain cases, tumor infiltrated T cells do not recognize tumor cells 
and hence they neither get activated nor proliferated in-vivo. In such cases, T cells’ 
usefulness becomes redundant. To improve the functional properties of these cells 
including recognition of antigen on cancer cells, an alternative approach is adopted 
Figure 3. 
Leading adoptive cellular therapy. Patients’ T cells utilized in TILs, TCR T cells and CAR T cell therapy. Major 
steps of these therapies discussed in the boxes.
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where patient’s T cells are genetically manipulated using gene editing technology. 
This also overcomes the problem of isolating pre-existing tumor-reacting T cells 
from patients with tumors of other types. Here the cells are made to express tumor 
antigen-specific TCRs, thus are effective in anti-tumor cytotoxic function [38].
There are two strategies to genetically modify the specificity of T cells. The 
patient’s cells can be genetically modified by integrating genes encoding either 
conventional alpha-beta TCRs, or Chimeric Antigen Receptors (CARs), specific for 
tumor antigen(s). To develop ACT by these mechanisms, TCR T cells or CAR T cells 
are manufactured by autologous T cells which are amended ex-vivo, expanded and 
re-injected in patient to fight against cancer cells (Figure 3b and c). The only differ-
ence remains in the mode of recognition of tumor antigen by these T cells (Figure 4).
3.2.1 TCR T cell therapy
The TCR is a specific receptor as well as characteristic marker on T cell surface. 
TCR complex is a di-sulphide linked membrane anchored heterodimer protein, 
consisting of two different peptide chains, TCR ɑ and TCR ß encircled by four CD3 
chains [39]. These TCR ɑ and ß chains recognize the polypeptide fragment pre-
sented by MHC molecule on cancer cells. The principal objective behind TCR T cell 
technology is to modify TCR binding to tumor antigen which as such shows poor 
affinity for antigens making them incompetent to recognize and kill tumor cells 
effectively [40]. Thus, making of high affinity TCR T cell requires identification 
of specific targets on cancer cells. This way the genetically engineered TCR shows 
augmented recognition specificity and affinity for tumor cells.
In a study done by Rapoport AP et al., an autologous T cell was engineered 
to express a high affinity TCR specific to identify naturally processed peptide 
shared by cancer-testis antigen New York Esophageal Squamous Cell Carcinoma-1 
(NY-ESO-1) and L antigen family member 1 (LAGE-1) to be used for multiple 
myeloma patients showing encouraging clinical response in 16 of 20 (80%) patients 
with advanced disease [41].
Figure 4. 
Molecular insights of cellular therapy. The boxes illustrate the salient features to determine the choice of ACT. 
In TILs and TCR T cells, the TCR ɑ and ß chains recognize the antigen presented with MHC molecule on 
cancer cells whereas CAR T cells recognize the tumor antigen independent of MHC. In TCR T cell, genetically 
engineered high affinity TCR recognizes tumor cells. In CAR T cell, a CAR, a scFv derived from variable 
regions of heavy and light chains of a monoclonal antibody against tumor antigen recognize tumor cells. 
CAR also consists of a trans-membrane domain; a hinge; one or more than one intracellular co-stimulatory 
molecules and a CD3z signaling domain. TCR T cell and CAR T cell therapy highly depend upon identification 
of unique antigen on cancer cells.
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In above mentioned TIL and TCR T cell-based therapies, there may be yet 
another problem which may be encountered when these expanded/modified cells 
still do not so efficiently recognize cancer cells. This happens when cancer cells 
smartly down regulate expression of specific MHC molecules and tumor antigen is 
presented without MHC complex and thus these T cells fail to recognize the target 
cancer cells. Fortunately, emergence of recombinant DNA technology and novel cell 
isolation techniques from blood have paved newer ways to cancer immunotherapy. 
Hence, to overcome this evading mechanism by cancer cells, T cells are genetically 
modified in such a way that they recognize cancer cells by a mechanism indepen-
dent of MHC [2, 42, 43].
3.2.2 CAR T cell therapy
This newer modality of modifying T cells is yet another type of ACT, where 
T cell are armed with a CAR, which can now make the T cells recognize cancer 
antigen without MHC molecules. Use of such modified T cells bearing CAR is 
called as CAR T cell for therapy. The concept of CAR T cell is based on the ability of 
genetically engineered patient’s own T cells to express a CAR, which is specific for a 
tumor antigen and therefore better in fighting cancer cells. A CAR consists of a scFv 
derived from variable region of heavy and light chains of a monoclonal antibody 
against tumor antigen to recognize tumor cells. Apart from this, a trans-membrane 
domain; a hinge; one or more than one intracellular co-stimulatory molecules and 
a CD3 zeta signaling domain are the part of CAR construct to make fully activated 
and functional T cell [2, 44].
Four generations of CARs have been developed, with subsequent generations 
being better than the previous ones with respect to cytotoxicity and shelf-life. First 
generation CARs had only single chain variable fragment (scFv) linked to CD3ζ or 
Fc receptor gamma signaling domain. With the subsequent additions of co-stim-
ulatory domains like CD28, CD 137, or OX40, second and third generation CARs 
have been created. Fourth generation CARs also called TRUCK (T cell redirected 
for universal cytokine killing) are armed with immune stimulatory cytokines that 
ameliorate the performance of CAR T cell with respect to its expansion, persistence, 
and resistance even in immunosuppressive tumor microenvironment [45, 46]. This 
therapy harnesses the power of immune system to fight the cancer but in contrast 
to the regular T cell receptor (TCRs), that recognize Ag, only when presented with 
MHC, CARs have the aptitude to redirect the effector function of T cell toward 
any tumor associated antigen (TAA) expressed on the tumor surface even without 
MHC. Once CAR of the T cell binds to its specific TAA, T cell gets activated through 
phosphorylation of immune receptor tyrosine-based activation motifs leading to 
cytokine secretion, T cell proliferation and cytotoxicity [47]. The word chimeric 
here signifies both, antigen binding, independent of MHC and T cell activation 
function into a single receptor (Figure 4).
Advantage of TCR T cell therapy over CAR T cell therapy is that these can rec-
ognize even deep-seated antigens fragment presented on MHC molecule in contrast 
to CAR T cell that recognize only cell surface proteins. So, TCR T cell therapy offer 
wider range of application but it is also MHC restricted and recognizes only those 
antigens presented on MHC molecule, a major drawback of TCR T cell therapy.
4. Opportunities and challenges
Like any other therapy, ACT also has success and failures. The therapy deals 
with T cells in two different ways, firstly, the natural T cell with antitumor activity 
Advances in Precision Medicine Oncology
8
and secondly, the genetically manipulated T cells, either the TCRs engineered or 
the receptor is chimeric. Thus, T cells’ immune responsiveness for tumor targeting 
functions discretely. Also, during the therapy, responsiveness and un-responsive-
ness of host is guided by many factors. Similarly, many criteria in preparation of the 
cells for therapy are the deciding factor for the effectiveness of the therapy, which in 
turn is decided by extent of tumor regression.
4.1 Tumor regression
Dramatic regression of variety of cancers, like melanoma, cervical cancer, lym-
phoma, leukemia, bile duct cancer, and neuroblastoma has been reported by the use 
ACT based approaches [2]. A number of cancer patients showed success using TILs, 
however, TIL therapy requires surgery and to obtain enough TILs is always a huge 
challenge technically. TILs expansion approach has been best used for the treatment 
of metastatic melanoma by Rosenberg et al. [48].
Applications of genetic manipulations in ACT have greatly contributed in 
improving the remission rate of treatment of various type of cancers [49]. For 
relapsed and refractory B-cell precursor Acute Lymphoblastic Leukemia in children 
and young adults, CAR T cell therapy was successful in 52 of 63 patients and three 
of every four patients did not show relapse in six months [50]. In another trial to 
treat refractory large B-cell lymphoma, CAR T cell therapy has shown promising 
results as it completely cured 54% patients, slowed tumor growth in 82% patients 
and there was no relapse in 40% patient even after 15.4 months [51]. CAR T cell 
therapy using B cell maturation antigen was tried on multiple myeloma patients and 
showed remission in 74% of patients [52].
4.2 Challenges
The failures of the therapy in any form have been associated with many factors. 
The extent to which the tumor cells can evade immune recognition and successfully 
employ immune suppression mechanisms leads to failure of ACT.
4.2.1 Cell selection
One of the factors which guards the successful use of ACT in humans is the 
identification of cells that can target antigens selectively expressed on the cancer 
and not on essential normal tissues. This criterion is the basis of the success of ACT. 
Also, sometimes immune cells lose their natural tendency to recognize and kill the 
tumor cells, leads to failure of therapy. Therefore, even though the cell selection is 
appropriate, sometimes success is not achieved.
4.2.2 Tumor microenvironment
Activities of tumor cells also play a key role in suppressing the effector function 
of immune cells used in ACT. The tumor cells along with their neighborhood con-
stitute a unique environment which is called as tumor microenvironment (TME). 
This has an ability to suppress host’s immune system by various mechanisms such 
as a) T cell exhaustion due to continuously changing antigen signatures on them; 
b) affects the cytotoxic function of T cells at the site of tumor and c) also the T 
cell trafficking [53]. To counter these immune suppressive mechanisms of TME, 
there are possible technologies available that locally deliver T cells to the TME and 
increase their proliferation, thus, could provide a means to treat inoperable solid 
tumors [54].
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4.2.3 Technical glitches
ACT involves different stages to generate clinical grade therapeutic cells and 
trained personnel to execute the technology. Therefore, it needs great care and 
precautions to avoid technological pitfalls.
4.2.3.1 Manufacturing
The technical issues are related to the manufacturing process of adoptive cellular 
material and the delivery platforms which also account for the success or failure of 
the ACT. During the ex-vivo expansion and genetic modification process, factors 
such as cell culture time, use of cytokines and use of vectors for gene transfer are 
the major concerns deciding the efficacy and survival of T cells being used in the 
therapy. Besides sometimes cancer specific T cells may not grow that well and not 
sufficient for infusion. At the same time efficacy of T cell may also change in ex-vivo 
growth conditions [55].
Major hurdle with regard to TCR T cell technology is related to its expansion 
which includes identifying of a good target, along with specific TCRs, screening 
for desirable TCR affinity. Also, TCR T cell therapy is MHC dependent and there 
is grave peril of hybridization between exogenous and endogenous chain causing 
recognition of auto-antigens thereby leading to graft-versus host disease [43].
Failures of the therapy with adverse outcomes have been reported due to some 
chromosomal DNA translocations and rearrangements during the preparation of 
the cells [56, 57].
4.2.3.2 Delivery system
A major limitation of adoptive T cell therapies is the delivery technology used 
in the patient. It is noted that the viability and function of the transplanted cells 
rapidly decline after administration [58]. Hence, different delivery technolo-
gies (nanoparticles or scaffolds) have been explored to improve success of ACT. 
Adjuvant-loaded nanoparticles, chemically conjugated to the surface of T cells 
to stimulate transplanted cells and minimize the systemic side effects have been 
designed [59]. Advantages of having a delivery system of T cells which has some 
immune stimulating mechanisms linked, may help the T cells to enter the tumor 
site and perform better results of the therapy. Apart from systemic administration 
route, biomaterials-based strategies have also been explored to locally deliver adop-
tive T cells to solid tumors [60, 61] as successful targeting of T cells to most solid 
cancers remain challenging [62]. To overcome the barrier of secluded location of 
solid tumors, local injection of T cell in brain tumors in mouse model has been tried 
and has shown better outcome than systemic administration [54].
Overall, biomaterial-mediated local T cell delivery approaches could improve 
the efficiency of adoptive T cell therapies for treating inoperable solid tumors by 
overcoming local immunosuppressive barriers. The usefulness of these therapies 
depends on how quickly T cells can be generated in tumors in-vivo using this 
approach relative to the time it takes to expand T cells ex-vivo.
4.2.4 Regulatory guidelines and cost
Regulatory guidelines are other part of the story that limit the use of any therapy 
where biological samples are used for therapeutic. There are certain considerations 
to be followed for minimal manipulation and homologous use of human cells, tis-
sues, and cellular and tissue-based products. Cellular & Gene Therapies are complex 
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products which are regulated by the Food and Drug Administration (FDA) in the 
United States. The European Union (EU), governs the regulation of all medicinal 
products for human use, including advanced therapy medicinal products (ATMPs), 
i.e., medicinal products comprised of cells, genes, or tissues to ensure the quality, 
safety, and efficacy of medicines placed on the market in the EU. The aims of EU are 
to ensure the quality, efficacy and most importantly safety of public health.
A very high treatment cost of ACT based immunotherapies has been another 
concern for its limited use [20, 63]. Cost of CAR-T cell has been curtailed by devel-
oping Universal CAR-T cell and CAR NK cell so that this therapy can be a hope for 
majority of cancer patients [64].
4.3 Advantages
There are many advantages with ACT that outweigh the conventional therapy.
One major advantage of TCR-T cell therapy is that it can target many TAA, 
even when these lie intracellular and are deep seated. Site directed injection of T 
cells into tumor giving superior result than systemic administration, is yet another 
favorable approach in cell-based therapies. A successful example of such applica-
tion is reported in brain tumors where T cells are injected into CSF directly [43, 54]. 
Similarly, next generation of CARs have enhanced the ability of T cells to destroy 
tumor by infiltrating into diseased tissue site and have potential to moderate tumor 
microenvironment by secreting pro-inflammatory cytokines and expand their own 
life span in-vivo [64].
CARs have another unique ability to recognize not only peptide but also carbo-
hydrate and glycolipid antigens, thus increasing their target antigen number and are 
also not MHC restricted.
5. Enhancing efficacy of ACT
The journey of development of ACT for cancer treatment has faced success and 
failures of the therapy in different cancer types. This has led to newer researches 
and explorations in various domains of the treatment by ACT. Work on improving 
effectiveness of therapy has contributed enormously and made difference in its 
outcomes. Following are some areas, which have been mentioned in this section 
about the efforts made toward enhancing efficacy of ACT.
5.1 Measuring effectiveness
Measuring effectiveness of any therapy is an essential part of it. It is critical to 
measure of cellular therapy’s effectiveness as variations may occur in various steps, 
starting from isolation of cells to its re-infusion and homing of effective cells to 
target the cancer cells (Figure 5). For this purpose, a therapeutic index (TI) has 
been developed [65].
TI of a drug is a quantitative assessment of the ratio of a drug dose that produces 
toxicity to the dose that yields a clinically effective response. ACT has complex bio-
distribution and also content dependent potency, so for this TI estimation depends 
on other factors as well. These include functional fitness of the product, vague 
pharmacokinetics due to trapping, sequestration and extravasations in nearby tissue 
and inconstant rate of expansion in-vivo. Addition factors also influence pharma-
cokinetics in case of solid tumors like difference in trafficking to benign and cancer 
tissue, immune suppression and cellular dysfunction due to unfavorable hostile 
metabolic state.
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Thus, TI of the ACT largely depends on generic factors (T cell potency and fit-
ness, Dispersion, Dysfunction, combinatorial therapies, comorbidities and micro-
biome) and TME-specific factors (Antigen availability, tumor, immune response 
related) [65].
5.2 Host conditioning
It is important to understand that anti-tumor efficacy of ACT greatly depends 
on the persistence of adoptively transferred T cells in the host. This is achieved by 
an optimal pre-conditioning of the host, an important part of pre-treatment proto-
col where lymphodepletion by chemotherapy and/or radiation therapy is done prior 
to therapy. The process of lymphodepletion is important to deplete T regulatory 
cells and lymphocytes, as these cells compete with the transferred cells for homeo-
static cytokines, interleukin 7 and IL15 and this needs to be minimized [66]. This 
may also be important to avoid excessive cytokine release by lymphocytes which 
causes adverse effect during the therapy. Host conditioning by either nonmyeloab-
lative chemotherapy or irradiation may induce high levels of IL-1β which increase 
the number and functionality of adoptively transferred T cells within the tumor 
and thus improves efficacy of ACT [67]. An FDA-approved reagent, fludarabine has 
predictable lymphodepleting kinetics and duration of action. Its use in a condition-
ing regimen, promotes homeostatic upregulation of cytokines and growth signals 
for T cell persistence [6]. The use of cytokine IL2 has also been recommended for 
better proliferation of the cells being used in this cellular therapy [2, 6].
5.3 Affinity of T cells
5.3.1 Selection of CARs with moderate affinity
Affinity of the immune cells in ACT is a highly critical criterion while using 
them for therapy. Optimum affinity is ensured during making of the cells. In TILs 
based therapy, it may not be that critical as there are no manipulations involved as 
such except increasing their numbers. However, while doing genetic manipulations, 
Figure 5. 
Scope to enhance therapeutic efficacy of ACT. The scope and limitations are two ends ACT. It may be viewed as 
the seesaw game. Increasing the scope will determine its future.
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it needs care especially when a gene fragment is being incorporated into the cell to 
express a chimeric receptor as in the case of CAR T cell therapy. High affinity CAR 
bearing cells are not the choice of cells as these might recognize the TAA present 
on the normal cells too and may cause on target/off tumor effect, an effect occurs 
when CAR T cells attack non-tumor cells expressing the target antigen. Thus, CAR 
selection is very important and ensured to be of low affinity so that it recognizes 
the antigen when it is present in high number as in case of tumor cells. This helps in 
recognizing only tumor cells and sparing normal cells [68].
5.3.2 Countering loss of antigen on cancer cells
Sometimes problem of therapy arises when the cancer cells start losing CAR-
targeted antigen on them and escape their detection by CAR T cells, thus avoid their 
killing. Such situation is countered by targeting multiple antigens with multiple 
CARs [69]. For this, anti-tag CARs (AT-CARs) have been developed by adding 
affinity-enhanced monomeric streptavidin2 (mSA2) biotin-binding domain in the 
CAR construct. Such novel mSA2CARs have an advantage that the T cells expressing 
such CARs can bind cancer cells coated with biotinylated antibodies [69]. Binding 
of such antibodies to cancer cells probably avoids the loss of antigen being targeted 
on them. Thus, recognition of cancer cells occurs followed by their killing by such 
CAR T cells without fail.
5.3.3 Formation of synapse
To further improve efficacy of CARs, small sized antibodies (variable heavy 
homodimers) or nanobodies are recommended to be used with CAR T cell prepara-
tion for infusion. These antibodies cause tight synapse formation between the target 
and effector cell, which is important for the initiation of immune signaling, thus 
effective T cell mediated killing [70].
5.3.4 CARs expressing Heparanase
It has been discovered that heparanase enzyme expression needs to be upregu-
lated in CAR T cells to penetrated tumor stroma which consists of heparin sulfate 
proteoglycane. In vitro expanded T cells show reduced heparanase expression as 
compared to activated immune cell, suggesting their compromised migration [71]. 
This drawback has been overcome by designing better CAR T cells which were 
engineered to express heparanase enzyme and therefore show greater capacity 
to infiltrate tumor stroma with enhanced anti-tumor activity in neuroblastoma 
xenograft model [72].
5.4 Dose
Next important part of therapy is the dose, i.e., number of the cells in the 
prepared fraction/dose. The dose frequency and the number of cells per dose to be 
used for infusion, both play a crucial role in outcome of the therapy. Proportion of 
immune cells responsible for tumor regression controls the success of ACT. Such as 
CD8+ enriched “young” tumor infiltrating lymphocytes show better response in the 
regression of metastatic melanoma compared to the crude fraction containing both 
CD8+ and CD4+ both proportions [73].
It has also been reported that the number of transfused CAR T cell needed for 
single transfusion is much less than that needed for TCR T cell therapy to produce 
equivocal response [43].
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5.5 Minimizing toxicities
ACT involves manipulation of immune system to improve its efficacy for 
specific killing of cancer cells. Such alterations may lead to exaggerated immune 
response and cause toxicities which are different from other cancer therapies. 
Thus, depending upon the type of mechanisms involved in these toxicities, discrete 
approaches are needed to minimize them. The possible toxicities observed and their 
 management are as follow:
a. On target/off tumor recognition develops a toxicity due to shared expression 
of target antigens by normal tissue leading to varying severity of adverse event 
from B cell aplasia to death. Hypogammaglobulinemia in B cell aplasia can be 
treated with intravenous immunoglobulin replacement therapy.
b. Anaphylaxis is seen in patients receiving genetically modified T cell as their 
antigen recognition domain in derived from murine mAb. Efforts are being 
made to humanize the expressed protein [74].
c. Graft versus host disease is commonly observed phenomena in immunothera-
pies. Infusion of isolated autologous TILs is the way to curtail it.
d. Cytokine Release Syndrome (CRS) is associated with overt activation of T cell, 
which leads to immune activation process with markedly elevated cytokines. 
It is seen in CAR T cell therapy and called as CAR T cell toxicity. CRS can be 
minimized by controlling the activity of CAR T cells. For this a bispecific adap-
tor has been designed which is a cancer specific ligand conjugated with fluo-
rescein. This specifically binds with cancer cells and tag them with fluorescein. 
CAR is so devised that it recognizes fluorescein and not tumor antigen. Thus, 
the bispecific adaptor bridges CAR T cell and its tumor target. Thus, availabil-
ity of bispecific adaptor regulates the killing of tumor cells and can control the 
CRS. Also, to subdue any CRS, rupture of bridge between CAR T cell to cancer 
cell can be lifesaving [74]. Other successful approaches to control CRS are 
immuno-suppression by systemic corticosteroids, IL-6 receptor blockade with 
mAb or lymphodepleting chemotherapy.
e. Immune effector cell associated neurotoxicity syndrome has also been 
reported, plausible explanation being elevated cytokine level.
f. Toxicity of T cell activation is also managed by inclusion of an “on switch” in 
CAR design which can make a hold on functional intensity and T cell activa-
tion. This requires selection of two target antigens that are co-expressed on 
malignant tissue making dual antigen binding a must for complete T cell acti-
vation. So normal tissue expressing one target antigen cannot provide complete 
activation and so limits this toxicity. Conversely, if dual antigens presentation 
is exclusive to normal tissue, inhibitory signaling in CAR design allow for selec-
tive targeting of malignant tissue expressing one antigen while normal tissue is 
spared.
g. Severe neurological side effects leading to coma and death are reported in 
patients treated with ACT using autologous T cell when T cells were modi-
fied with Melanoma-associated antigen 3 (MAGE-A3) antigen specific TCRs 
(MAGE-A3 is cancer testis antigen never expressed in normal tissue). These 
TCRs recognize the different but similar epitopes of especially MAGE-A12 and 
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possibly MAGE-A1, A8, A9 expressed in human brain. So unfortunately, strate-
gies to enhance TCR affinity to neoantigens on tumor may lead to unantici-
pated toxicities thus warrants need of improved preclinical testing methods to 
better enable prediction of TCRs specificity.
6. Conclusions
Cancer is a multifactorial disease with varieties of treatment options available, 
depending upon the location, drug delivery and stage of cancer. Optimization of 
immune response to curb the growth, proliferation and containment of cancer has 
been chosen in TIL, TCR T cell and CAR T cell therapy. Growing technologies in cell 
biology are improving the future promises for further breakthroughs in the T cell 
ACT field. Various future domains, which are being explored for further improve-
ments are being discussed below [75]:
a. The TME and other immune escape mechanisms are the challenges to ACT for 
solid tumors. For this, individualized approaches and strategies combining 
treatments targeting different immunotherapeutic aspects will be needed in 
order to expand the applicability and improve the response rates in future.
b. Cross reactivity is seen in antigen specific TCRs, which leads to fatal outcomes, 
needs newer platforms for preclinical screening, such as X-scan.
c. Newer approaches to manage abnormalities of blood vessels and endothelial 
cells that hinder T cell infiltration into tumors may be tried with inhibitory 
molecules.
d. Scope to make ACT more effective in solid tumors can be tested by reducing 
high interstitial pressure and dense extracellular matrix of solid tumor tissue 
by angiotensin inhibition.
e. Another strategy to enhance the antitumor immunity of infused T cell may be 
explored through depletion of tumor-associated macrophages.
f. Also, combination of these therapies is providing newer opportunities to 
personalized immunotherapy due to individual variation in immune response.
In short, advantages versus toxicities of the anti-cancer therapy have to be 
considered before deciding the treatment modalities. Ultimately, successful imple-
mentation of ACT as the clinical program and cost minimization will determine its 
success across the globe.
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